Therapy Area

News

Codagenix pursues RSV vaccine development amid unexpected challenges

Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.

Akosua Mireku

Cardiovascular

View More

Central Nervous System

View More

Immunology

View More

Infectious Disease

View More

Oncology

View More

Respiratory

View More
close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *

Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close